125 related articles for article (PubMed ID: 33855021)
1. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response.
Hua YQ; Zhang K; Sheng J; Ning ZY; Li Y; Shi WD; Liu LM
Front Cell Dev Biol; 2021; 9():641836. PubMed ID: 33855021
[TBL] [Abstract][Full Text] [Related]
2. Nucleobindin 1 controls the unfolded protein response by inhibiting ATF6 activation.
Tsukumo Y; Tomida A; Kitahara O; Nakamura Y; Asada S; Mori K; Tsuruo T
J Biol Chem; 2007 Oct; 282(40):29264-72. PubMed ID: 17686766
[TBL] [Abstract][Full Text] [Related]
3. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
4. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells
Xie F; Zheng Y; Fu W; Chi B; Wang X; Zhang J; Gu J; Yin J; Zhou Q; Guo S; Cai L; Yang J; Liu S; Wang H
Front Oncol; 2023; 13():1138238. PubMed ID: 37182151
[TBL] [Abstract][Full Text] [Related]
5. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Takayama T; Han H; Fillat C; Kinugasa Y; Goel A
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672630
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Wnt/β-catenin Signaling in PDAC via METTL16-mediated N6-methyladenosine Modification of DVL2.
Yu L; Lu J; Xie N; Fang L; Chen S; Wu Y; Wang X; Li B
J Cancer; 2023; 14(16):2964-2977. PubMed ID: 37859814
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
[TBL] [Abstract][Full Text] [Related]
8. Expression of nucleobindin 1 (NUCB1) in pancreatic islets and other endocrine tissues.
Williams P; Tulke S; Ilegems E; Berggren PO; Broberger C
Cell Tissue Res; 2014 Nov; 358(2):331-42. PubMed ID: 25038744
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Notch3 links TIMP3 inhibition to suppress aggressive phenotypes of pancreatic ductal adenocarcinoma.
Chiu TJ; Chen YJ; Lan J; Chen YY; Chen YC; Lin HW; Tsai HT; Lin YS; Hsiao CC; Chen CH
Am J Cancer Res; 2021; 11(11):5609-5624. PubMed ID: 34873483
[TBL] [Abstract][Full Text] [Related]
10. An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer.
Robinson CM; Talty A; Logue SE; Mnich K; Gorman AM; Samali A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445669
[TBL] [Abstract][Full Text] [Related]
11. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
13. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
[TBL] [Abstract][Full Text] [Related]
14. Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle.
Albahde MAH; Zhang P; Zhang Q; Li G; Wang W
Front Oncol; 2020; 10():49. PubMed ID: 32117719
[No Abstract] [Full Text] [Related]
15. Nucleobindin 1 (NUCB1) is a Golgi-resident marker of neurons.
Tulke S; Williams P; Hellysaz A; Ilegems E; Wendel M; Broberger C
Neuroscience; 2016 Feb; 314():179-88. PubMed ID: 26666627
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.
Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L
J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254
[TBL] [Abstract][Full Text] [Related]
17. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.
You N; Li J; Gong Z; Huang X; Wang W; Wang L; Wu K; Zheng L
Mol Carcinog; 2017 Feb; 56(2):607-624. PubMed ID: 27350032
[TBL] [Abstract][Full Text] [Related]
18. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
[TBL] [Abstract][Full Text] [Related]
19. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.
Yang C; Zhu S; Yang H; Deng S; Fan P; Li M; Jin X
Am J Cancer Res; 2019; 9(8):1722-1733. PubMed ID: 31497353
[TBL] [Abstract][Full Text] [Related]
20. Expression and correlation of COX-2 and NUCB1 in colorectal adenocarcinoma.
Zhang Y; Zhang G; Zhong J; Li A; Wu Y; Guo Z
PeerJ; 2023; 11():e15774. PubMed ID: 37547718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
